Tom Powles IMVIGOR011
Tom Powles/bartscancer.london

Tom Powles Shared Positive Results from IMVIGOR011 Bladder Cancer Trial

Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:

“IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last.”

IMVIGOR011

Read More.

More posts featuring Tom Powles on OncoDaily.